Security key
449778109
IO Biotech, Inc. - Common Stock, $0.001 Par Value Per Share (IOBTQ)
CUSIP: 449778109
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, $0.001 Par Value Per Share
- Shares outstanding
- 73,755,848
- Total 13F shares
- 9,895,875
- Share change
- -8,286,832
- Total reported value
- $3,589,663
- Price per share
- $0.36
- Number of holders
- 21
- Value change
- -$13,417,589
- Number of buys
- 14
- Number of sells
- 19
Report period
Q3 2025
Institutions
21
Top holders
10
IOBTQ full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
IO Biotech, Inc. SEC filings
IO Biotech, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 449778109
Recent filing periods:
Top shareholders of IOBTQ - IO Biotech, Inc. - Common Stock, $0.001 Par Value Per Share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. |
13D/G
|
— |
3.8%
|
2,631,578
|
$2,578,946 | $0 | 31 Dec 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
8.4%
|
6,173,439
|
$8,581,080 | — | 30 Jun 2025 | |
| Novo Holdings A/S |
3/4/5
13F
|
10%+ Owner · Company |
4.5%
from 13F
|
6,823,584
mixed-class rows
|
$5,709,989 | — | 25 Jul 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.9%
|
2,105,262
|
$2,926,314 | — | 30 Jun 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
2.7%
|
1,972,073
|
$2,741,181 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.2%
|
1,615,074
|
$2,244,953 | — | 30 Jun 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
1.2%
|
864,197
|
$1,201,234 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.89%
|
653,678
|
$908,612 | — | 30 Jun 2025 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.47%
|
347,408
|
$482,896 | — | 30 Jun 2025 | |
| Dauntless Investment Group, LLC |
13F
|
Company |
0.44%
|
324,389
|
$450,901 | — | 30 Jun 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.26%
|
192,670
|
$267,811 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.19%
|
139,300
|
$193,627 | — | 30 Jun 2025 | |
| SECTORAL ASSET MANAGEMENT INC |
13F
|
Company |
0.16%
|
117,691
|
$163,590 | — | 30 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
75,000
|
$104,250 | — | 30 Jun 2025 | |
| Marex Group plc |
13F
|
Company |
0.06%
|
45,000
|
$62,550 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
33,307
|
$46,296 | — | 30 Jun 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.04%
|
29,189
|
$40,573 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.04%
|
28,866
|
$40,124 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.04%
|
25,946
|
$36,065 | — | 30 Jun 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0.03%
|
24,217
|
$33,662 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.03%
|
23,366
|
$32,000 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
13,259
|
$18,430 | — | 30 Jun 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.02%
|
13,096
|
$18,203 | — | 30 Jun 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.01%
|
10,385
|
$14,435 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0%
|
1,000
|
$1,390 | — | 30 Jun 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
314
|
$436 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
132
|
$183 | — | 30 Jun 2025 | |
| Invest A/s Lundbeckfond |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
21,851,920
mixed-class rows
|
$14,438,960 | — | 09 Aug 2023 | |
| Vivo Capital IX, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
12,346,878
mixed-class rows
|
$9,510,598 | — | 09 Aug 2023 | |
| HBM Healthcare Investments (Cayman) Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,690,545
|
$2,784,714 | — | 09 Nov 2021 | |
| Kurma Partners |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
623,428
|
$645,248 | — | 09 Aug 2023 | |
| Claus A. Andersson |
3/4/5
|
Director |
—
class O/S missing
|
1,791,490
|
$1,854,192 | — | 09 Nov 2021 | |
| Vanessa Malier |
3/4/5
|
Director |
—
class O/S missing
|
430,477
|
$445,544 | — | 09 Nov 2021 | |
| Amy Sullivan |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
299,632
mixed-class rows
|
$70,041 | — | 02 Apr 2025 | |
| Mai-Britt Zocca |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
656,471
mixed-class rows
|
$61,911 | — | 02 Apr 2025 | |
| Qasim Iftikhar Ahmad |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
246,350
mixed-class rows
|
$26,553 | — | 02 Apr 2025 | |
| Heidi Hunter |
3/4/5
|
Director |
—
mixed-class rows
|
50,144
mixed-class rows
|
$20,884 | +$20,885 | 05 Jun 2025 | |
| Devin W. Smith |
3/4/5
|
General Counsel |
—
mixed-class rows
|
156,938
mixed-class rows
|
$13,720 | — | 02 Apr 2025 | |
| Eva Ehrnrooth |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Muhammad Al-Hajj |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Keith A. Vendola |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
69,469
|
— | — | 04 Nov 2021 | |
| Brian Burkavage |
3/4/5
|
Chief Accounting Officer |
—
class O/S missing
|
65,000
|
— | — | 02 Apr 2025 | |
| Jack Nielsen |
3/4/5
|
Director |
—
class O/S missing
|
41,533
|
— | — | 08 Jun 2023 | |
| Christian E. Elling |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| David V Smith |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| Helen Louise Collins |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| Kathleen Sereda Glaub |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| Peter Hirth |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 |
Institutional Holders of IO Biotech, Inc. - Common Stock, $0.001 Par Value Per Share (IOBTQ) as of Q3 2025
As of 30 Sep 2025,
IO Biotech, Inc. - Common Stock, $0.001 Par Value Per Share (IOBTQ) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,895,875 shares.
The largest 10 holders included
NOVO HOLDINGS A/S, Ikarian Capital, LLC, MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, BANK OF AMERICA CORP /DE/, MORGAN STANLEY, BOOTHBAY FUND MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, Point72 Asset Management, L.P., and XTX Topco Ltd.
This page lists
21
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
26
Q3 2025 holders
21
Holder diff
-5
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.